Solana Beach, CA, United States of America

Jennifer Diane Venable

This inventor holds 52 USPTO granted patents and 6 published patent applications, plus 7 CIPO patents and 15 EPO patents, primarily in Kinase Inhibitors (CPC class C07D). Top assignees: Janssen Pharmaceutica Nv, Respivert Limited, Topivert Pharma Limited. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jennifer Diane Venable. Retrieved from https://idiyas.com/inventor/jennifer-diane-venable

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 52 (Patent Applications = 6)

% Patents Active = 69.2

CIPO Patents = 7

EPO Patents = 15 (Patent Applications = 13)

Average Co-Inventor Count = 5.4

ph-index = 8

Forward Citations = 173(Granted Patents)

Forward Citations (Not Self Cited) = 135(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Del Mar, CA (US) (2009)
Solana Beach, CA (US) (2007 - 2024)

Company Filing History:

44 out of 2,101

Janssen Pharmaceutica Nv

Topivert Pharma Limited

patents

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Bruton's Tyrosine Kinase

p38 MAP Kinase

KEAP1-Nrf2

JAK Family Kinases

Histamine H4 Receptor

Imidazopyridazine

Imidazopyrrolopyridine

Pyrazolyl-Ureas

2,4-Diaminopyrimidine

Thieno-Pyrimidine

Furo-Pyrimidine

Quinoline Antagonists

52 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12622910 - Inhibitors of Bruton's tyrosine kinase and methods of their use (2026-05-12),

2. 12215111 - Imidazopyridazine IL-17 inhibitor compounds (2025-02-04),

3. 12065446 - Inhibitors of Bruton's tyrosine kinase and method of their use (2024-08-20),

4. 11897900 - Inhibitors of KEAP1-Nrf2 protein-protein interaction (2024-02-13),

5. 11827638 - Imidazopyrrolopyridine as inhibitors of the JAK family of kinases (2023-11-28),

6. 11634406 - Inhibitor of p38 MAP kinase (2023-04-25),

7. 11427601 - Inhibitors of KEAP1-Nrf2 protein-protein interaction (2022-08-30),

8. 11319329 - Inhibitors of Bruton's tyrosine kinase and methods of their use (2022-05-03),

9. 11142515 - Pyrazolyl-ureas as kinase inhibitors (2021-10-12),

10. 10981911 - Imidazopyrrolopyridine as inhibitors of the JAK family of kinases (2021-04-20),

11. 10947252 - Inhibitors of KEAP1-Nrf2 protein-protein interaction (2021-03-16),

12. 10934310 - Inhibitors of Bruton's tyrosine kinase and method of their use (2021-03-02),

13. 10822348 - Inhibitors of Bruton's tyrosine kinase and methods of their use (2020-11-03),

14. 10815217 - Inhibitor of p38 MAP kinase (2020-10-27),

15. 10800792 - Inhibitors of Bruton's tyrosine kinase and method of their use (2020-10-13),

Title: Innovations and Contributions of Jennifer Diane Venable

Introduction

Jennifer Diane Venable, based in Solana Beach, California, is a prominent inventor in the pharmaceutical field with an impressive portfolio of 51 patents. Her groundbreaking work focuses on developing compounds for treating various medical conditions, demonstrating her commitment to advancing healthcare through innovative solutions.

Latest Patents

Among her latest inventions, Venable has developed "Imidazopyridazine IL-17 inhibitor compounds." This patent discloses compounds designed to treat or ameliorate IL-17 mediated syndromes, disorders, and diseases. The specifics of these compounds include various defined substituents, which enhance their therapeutic potential. Another significant contribution is her patent for "Inhibitors of Bruton's tyrosine kinase and method of their use." This invention outlines a class of compounds and their methods of preparation and application, underscoring her ability to create versatile therapeutic agents.

Career Highlights

Venable's career spans several key organizations where she has made significant contributions. Notably, she has worked at Janssen Pharmaceutica, a subsidiary of Johnson & Johnson, and Respivert Limited, a company known for its innovative approaches in respiratory therapeutics. Her expertise and inventions continue to push the boundaries of medical science.

Collaborations

Throughout her career, Jennifer Diane Venable has collaborated with distinguished professionals such as James Patrick Edwards and David E. Kindrachuk. These collaborations highlight the importance of teamwork in the research and development of life-saving therapies and reinforce Venable's role as a pivotal contributor in the field.

Conclusion

Jennifer Diane Venable's work exemplifies the spirit of innovation in the pharmaceutical industry. Her extensive patent portfolio and collaborative efforts underscore her dedication to improving health outcomes through novel inventions. As she continues her journey, the impact of her contributions will undoubtedly resonate within the field for years to come.

Profile summary based on public USPTO records.